Literature DB >> 8922813

Characteristics of lipid-based formulations that influence their biological behavior in the plasma of patients.

K M Wasan1, G Lopez-Berestein.   

Abstract

Patients with cancer and infectious diseases often have changes in the composition and concentration of their different blood components. These changes include variations in the composition and concentration of plasma lipoprotein lipids, in transfer rates of endogenous lipid between different lipoprotein classes, and in concentrations of phagocytic cells (i.e., monocytes and macrophages). It appears that the interaction of many lipid-based drug formulations with plasma lipoproteins and blood phagocytic cells may be responsible for the unpredictable pharmacokinetics and pharmacodynamics of those compounds when administered to patients with diseases. This review examines the potential mechanisms that may explain the biological behavior of lipid-based drug formulations used in the treatment of infectious diseases and cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8922813     DOI: 10.1093/clinids/23.5.1126

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  8 in total

Review 1.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

2.  Physical characteristics and lipoprotein distribution of liposomal nystatin in human plasma.

Authors:  K M Wasan; M Ramaswamy; S M Cassidy; M Kazemi; F W Strobel; R L Thies
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

3.  Plasma protein distribution and its impact on pharmacokinetics of liposomal amphotericin B in paediatric patients with malignant diseases.

Authors:  Ying Hong; Peter J Shaw; Bruce N Tattam; Christa E Nath; John W Earl; Katherine R Stephen; Andrew J McLachlan
Journal:  Eur J Clin Pharmacol       Date:  2006-12-19       Impact factor: 2.953

Review 4.  Newer antifungal agents.

Authors:  Walid Abuhammour; Eyassu Habte-Gaber
Journal:  Indian J Pediatr       Date:  2004-03       Impact factor: 1.967

Review 5.  Amphotericin B formulations: a comparative review of efficacy and toxicity.

Authors:  Richard J Hamill
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

6.  Pharmacokinetics of a controlled-release liposome-encapsulated hydromorphone administered to healthy dogs.

Authors:  L J Smith; B KuKanich; B K Hogan; C Brown; T D Heath; L A Krugner-Higby
Journal:  J Vet Pharmacol Ther       Date:  2008-10       Impact factor: 1.786

7.  Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens.

Authors:  William W Hope; Joanne Goodwin; Timothy W Felton; Michael Ellis; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2012-08-06       Impact factor: 5.191

Review 8.  Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy.

Authors:  Hsin-I Chang; Ming-Kung Yeh
Journal:  Int J Nanomedicine       Date:  2011-12-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.